KIR3DL1 and neuroblastoma: We have previously shown that this interaction of inhibitory KIR2DL2 and KIR3DL1 with their ligands was associated with improved outcome in follicular lymphoma and neuroblastoma patients receiving rituximab maintenance therapy and dinutuximab monoclonal antibody (mAb) immunotherapy, respectively [9, 11].